Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections

Introduction: The present study was performed to evaluate the efficacy and safety of a 10-day regimen of prulifloxacin 600 mg once daily as compared to ciprofloxacin 500 mg twice daily in the treatment of patients with complicated urinary tract infections (UTIs). Materials and Methods: 257 patients (mean age ± SD 62.3 ± 16.5) were enrolled and orally treated with prulifloxacin (127 patients) or ciprofloxacin (130 patients). The study was designed as a randomized, double-blind, double-dummy, controlled clinical trial. The primary efficacy parameter was the eradication of infecting strains (<10³ cfu/ml). The clinical outcome and tolerability were also assessed. Results: At baseline, the most common infecting strains were Escherichia coli (62.8%), Proteus mirabilis (7.1%) and Klebsiella pneumoniae (4.1%). At the early follow-up, the rate of patients showing successful treatment was 90.8% in the prulifloxacin group, and 77.8% in the ciprofloxacin group (p = 0.008). A positive clinical outcome was observed in 94.8 and 93.3% of prulifloxacin- and ciprofloxacin-treated patients. Both drugs were well tolerated. Two patients dropped out for treatment-related adverse events. Conclusions: The high urinary concentrations of prulifloxacin, combined with a broad-spectrum antimicrobial activity, allow its use in the empiric therapy of UTIs.

show abstract

“…Similar results at long-term follow-ups were reported in other studies performed with ciprofl oxacin and gatifl oxacin [15,16] .…”

Section: Discussionsupporting

confidence: 90%

Prulifloxacin versus Ciprofloxacin in the Treatment of Adults with Complicated Urinary Tract Infections

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In a multicentre, randomised clinical study, a once-daily regimen with 500 mg conventional ciprofloxacin was compared with a twice-daily regimen with 250 mg orally. Statistical analysis regarding the elimination of bacteriuria using the 95% confidence interval showed a difference of up to 18.4% between the two treatment groups in favour of the 250 mg twicedaily regimen [17]. Therefore, the overall aim of clinical development of ciprofloxacin XR was to extend the pharmacokinetic and pharmacodynamic profile achieved with conventional, immediate-release, twice-daily ciprofloxacin.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics of ciprofloxacin XR (1000mg) versus levofloxacin (500mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose

Wagenlehner

Kinzig‐Schippers

Tischmeyer

et al. 2006

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…Starting from timepoint T0, patients received an oral oncedaily dose of 500 mg ciprofloxacin [33] for a period of 6 weeks. The quinolone was associated with a macrolide as described by Tsukamoto et al [19].…”

Section: Therapeutic Protocolmentioning

confidence: 99%

Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis

Magri

Trinchieri

Pozzi

et al. 2007

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections

Cited by 25 publications

References 5 publications

Prulifloxacin versus Ciprofloxacin in the Treatment of Adults with Complicated Urinary Tract Infections

Prulifloxacin versus Ciprofloxacin in the Treatment of Adults with Complicated Urinary Tract Infections

Pharmacokinetics of ciprofloxacin XR (1000mg) versus levofloxacin (500mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose

Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis

Contact Info

Product

Resources

About